Showing Results for
- Academic Journals (30)
Search Results
- 30
Academic Journals
- 30
- Search Terms:
- 1From: Nature Reviews Drug Discovery. (Vol. 9, Issue 6) Peer-ReviewedThe European Medicines Agency has released a draft guideline on the use of pharmacogenetic methods in the evaluation of the pharmacokinetics of new therapies. The lowdown: Assessing the pharmacokinetics of an...
- 2From: Nature Reviews Drug Discovery. (Vol. 9, Issue 6) Peer-ReviewedBrain-derived neurotrophic factor (BDNF) has an important role in supporting neuronal survival, which has encouraged studies of its therapeutic potential for neurodegenerative disorders such as Alzheimer's disease....
- 3From: Nature Reviews Drug Discovery. (Vol. 9, Issue 6) Peer-ReviewedA small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo Cerchietti, L. C. et al. Cancer Cell 17, 400-411 (2010) The BCL6 transcription factor is the most common oncogene involved in diffuse large...
- 4From: Nature Reviews Drug Discovery. (Vol. 9, Issue 6) Peer-ReviewedThe Indian Patent office (IPO) has overturned Roche's patent (IN 207232) for Valcyte (valgancyclovir), which was granted in 2007, following a challenge by generics manufacturers and patient advocacy groups. Valcyte,...
- 5From: Nature Reviews Drug Discovery. (Vol. 9, Issue 6) Peer-ReviewedA pioneering Phase II trial reported at the American Association for Cancer Research 2010 annual meeting (abstract number LB-1) is the first to demonstrate the use of multiple biomarkers to guide the treatment of...
- 6From: Nature Reviews Drug Discovery. (Vol. 9, Issue 6) Peer-ReviewedAberrant signalling of the Notch pathway has been linked to numerous diseases, particularly many cancers. Although the potential of therapeutically targeting this pathway in cancer is being actively investigated,...
- 7From: Nature Reviews Drug Discovery. (Vol. 9, Issue 6) Peer-ReviewedN-myristoyltransferase inhibitors as new leads to treat sleeping sickness Frearson, J. A. et al. Nature 646, 728-732 (2010) This paper describes the validation of a molecular target and the discovery of associated...
- 8From: Nature Reviews Drug Discovery. (Vol. 9, Issue 6) Peer-ReviewedAlthough drug development has advanced for autoimmune diseases, many current therapies are hampered by adverse effects and the frequent destruction or inactivation of healthy cells in addition to pathological cells....
- 9From: Nature Reviews Drug Discovery. (Vol. 9, Issue 6) Peer-ReviewedWithin the next decade, Asia is expected to overtake Europe in pharmaceutical sales, driven by growth in key emerging markets. For example, China is predicted to be the second largest pharmaceutical market after the...
- 10From: Nature Reviews Drug Discovery. (Vol. 9, Issue 6) Peer-ReviewedGiven the key roles of mitochondria in cellular energy production and apoptosis regulation, it is not surprising that their importance in a wide range of diseases is being increasingly appreciated. Two reviews this...
- 11From: Nature Reviews Drug Discovery. (Vol. 9, Issue 6) Peer-ReviewedMitochondria are the cells' powerhouse, but also their suicidal weapon store. Dozens of lethal signal transduction pathways converge on mitochondria to cause the permeabilization of the mitochondrial outer membrane,...
- 12From: Nature Reviews Drug Discovery. (Vol. 9, Issue 6) Peer-ReviewedThe speed, cost and accessibility of DNA sequencing has been transformed in recent years by new technologies, opening up exciting possibilities for disease diagnosis and therapeutic intervention. This month, we...
- 13From: Nature Reviews Drug Discovery. (Vol. 9, Issue 6) Peer-ReviewedSanofi-Aventis has signed an agreement with CureDM, entitling Sanofi-Aventis to exclusive worldwide rights to develop and market Pancreate--a first-in-class peptide therapeutic that may have the potential to stimulate...
- 14From: Nature Reviews Drug Discovery. (Vol. 9, Issue 6) Peer-ReviewedOncology has become one of the major focus areas for pharmaceutical and biotechnology companies. In 2009, ~16,000 of the ~40,000 Phase I, II and III trials listed on ClinicalTrials.gov were related to cancer (~40%)....
- 15From: Nature Reviews Drug Discovery. (Vol. 9, Issue 6) Peer-ReviewedAcutely inflamed tissue returns to homeostasis through active resolution processes, but in chronic diseases such as arthritis, painful inflammation persists. The resolvins--biologically active lipids derived from...
- 16From: Nature Reviews Drug Discovery. (Vol. 9, Issue 6) Peer-ReviewedMerck has seen certain claims of its patent that protects its blockbuster cholesterol drug Zetia (ezetimibe) rejected in a dispute with generics manufacturer Glenmark, but has reached a settlement agreement with the...
- 17From: Nature Reviews Drug Discovery. (Vol. 9, Issue 6) Peer-ReviewedThe Board of Patent Appeals and Interferences, part of the US Patent and Trademark Office (PTO), has decided that a controversial patent (US 7,029,913) that covers methods of preparing and isolating human pluripotent...
- 18From: Nature Reviews Drug Discovery. (Vol. 9, Issue 6) Peer-ReviewedA limitation of many anticancer drugs is their inability to target and penetrate tumour tissue, leading to reduced efficacy and nonspecific adverse effects on normal cells. In a study published in Science, researchers...
- 19From: Nature Reviews Drug Discovery. (Vol. 9, Issue 6) Peer-ReviewedDespite receiving a positive advisory committee vote of 9-3, the US FDA rejected InterMune's new drug application for pirfenidone, an orphan drug in development for the treatment of idiopathic pulmonary fibrosis. The...
- 20From: Nature Reviews Drug Discovery. (Vol. 9, Issue 6) Peer-ReviewedA new first-in-class compound for tackling hepatitis C virus (HCV) infection, which targets the NS5A protein of HCV, has shown potent antiviral effects in a Phase I trial of patients chronically infected with HCV....